ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.91 CNY | +2.83% |
|
-0.40% | +39.87% |
| Sales 2024 * | 2.63B 363M | Sales 2025 * | 3.23B 446M | Capitalization | 10.46B 1.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 547M 75.55M | Net income 2025 * | 664M 91.71M | EV / Sales 2024 * | 3.98 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.24 x |
| P/E ratio 2024 * |
19.1
x | P/E ratio 2025 * |
15.7
x | Employees | 2,687 |
| Yield 2024 * |
4.23% | Yield 2025 * |
5.16% | Free-Float | 42.74% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.83% | ||
| 1 week | -0.40% | ||
| Current month | +15.49% | ||
| 1 month | +15.49% | ||
| 3 months | +47.77% | ||
| 6 months | +43.78% | ||
| Current year | +39.87% |
1 week
13.94
15.31
1 month
12.7115.31
Current year
8.3615.31
1 year
8.3615.31
3 years
6.8315.55
5 years
4.6415.55
10 years
3.3318.18
| Managers | Title | Age | Since |
|---|---|---|---|
Tao Wang
CEO | Chief Executive Officer | 56 | 18-01-15 |
Yue Hong Shen
BRD | Director/Board Member | 49 | 21-01-24 |
Li Ming Yao
BRD | Director/Board Member | 44 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ping Wang
BRD | Director/Board Member | 49 | 21-01-24 |
You Qiang Yu
CHM | Chairman | 62 | 03-08-26 |
Xue Gen Zheng
BRD | Director/Board Member | 59 | 08-01-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 14.91 | +2.83% | 29,895,480 |
| 24-04-29 | 14.5 | +1.97% | 20,424,720 |
| 24-04-26 | 14.22 | -2.20% | 25,782,580 |
| 24-04-25 | 14.54 | -0.55% | 16,070,060 |
| 24-04-24 | 14.62 | +0.69% | 18,082,340 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Zhejiang Jolly Pharmaceutical Co., Ltd. is a China-based company principally engaged in research, development, manufacture and sales of medicinal fungi series products. The Companyâs main business is mainly involved in pharmaceutical manufacturing, among which the activities are involved in manufacture and sale of active pharmaceutical ingredients, tablets, capsules, granules, Lyophilized powders and other products. The main products include Wuling series, bailing tablets series and Chinese medicine drinking tablets series, among others. Through its subsidiaries, the Company is also engaged in pharmaceutical circulation.
Sector
Pharmaceuticals
Calendar
2024-05-10
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.91
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +39.87% | 1.44B | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.18B | |
| +3.98% | 3.16B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- 300181 Stock
